Case Study
Neuroblastoma Case Study:
Achieving rapid access for paediatric patients with a deadly disease
![](https://i0.wp.com/latticepointconsulting.com/wp-content/uploads/2019/06/case-study-background.png?resize=167%2C187&ssl=1)
Background
- A small pharma without a market access team in-licensed an immunotherapy only months prior to commercial launch
- Product was granted marketing authorization by CHMP under exceptional circumstances
- LatticePoint developed the pricing strategy for originator/R&D company and was asked by the acquiror to provide the market access support and execution
![](https://i0.wp.com/latticepointconsulting.com/wp-content/uploads/2019/06/case-study-engagement.png?resize=211%2C216&ssl=1)
LatticePoint Engagement
- Develop launch sequencing to optimize list prices across the EU and minimize reference pricing impact on revenue
- Evaluate Early Access Program (EAP) opportunities for patient access and revenue generation, including application preparation
- Evaluate and develop Managed Entry Agreements (MEAs) for key markets based on evidence available
- Develop of reimbursement dossiers, including:
- Synthesizing clinical trial data and data gaps to support HTA evaluations
- Reinforcing evidence arguments via systematic literature reviews (SLRs), meta-analyses and indirect comparisons
- Developing cost effectiveness and budget impact models (as relevant)